Research Analysts Offer Predictions for MREO Q1 Earnings

Mereo BioPharma Group plc (NASDAQ:MREO) – Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Mereo BioPharma Group in a research note issued on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz expects that the company will earn $0.07 per share for the quarter. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.08 EPS and FY2026 earnings at ($0.03) EPS.

Mereo BioPharma Group (NASDAQ:MREO) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03).

Other analysts also recently issued research reports about the stock. Needham & Company LLC restated a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a report on Wednesday, March 26th. Lifesci Capital initiated coverage on shares of Mereo BioPharma Group in a report on Tuesday, December 24th. They set an “outperform” rating and a $10.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a research note on Tuesday, March 18th. JPMorgan Chase & Co. began coverage on shares of Mereo BioPharma Group in a research report on Thursday. They set an “overweight” rating and a $7.00 price objective for the company. Finally, Jefferies Financial Group began coverage on Mereo BioPharma Group in a report on Friday, December 6th. They issued a “buy” rating and a $7.00 price target for the company. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Mereo BioPharma Group presently has an average rating of “Buy” and an average price target of $7.71.

Mereo BioPharma Group Stock Down 4.6 %

Shares of NASDAQ:MREO opened at $2.30 on Monday. Mereo BioPharma Group has a 52-week low of $2.22 and a 52-week high of $5.02. The stock has a market cap of $356.84 million, a P/E ratio of -38.33 and a beta of 1.03. The business has a fifty day moving average of $2.72 and a two-hundred day moving average of $3.48.

Institutional Trading of Mereo BioPharma Group

Several hedge funds and other institutional investors have recently made changes to their positions in MREO. Newbridge Financial Services Group Inc. acquired a new stake in Mereo BioPharma Group in the fourth quarter valued at about $37,000. Jump Financial LLC purchased a new position in shares of Mereo BioPharma Group during the 4th quarter worth approximately $39,000. Sheets Smith Investment Management acquired a new stake in shares of Mereo BioPharma Group in the 4th quarter valued at approximately $59,000. Virtus ETF Advisers LLC purchased a new stake in shares of Mereo BioPharma Group in the fourth quarter valued at approximately $67,000. Finally, Avanza Fonder AB purchased a new position in Mereo BioPharma Group in the fourth quarter worth $69,000. Hedge funds and other institutional investors own 62.83% of the company’s stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.